Bluejay Diagnostics (BJDX) ties director's options to FDA device clearance

Bluejay Diagnostics granted director Wurth Douglas Clark 100,000 stock options exercisable only upon FDA clearance of their Symphony IL-6 point-of-care testing device, aligning executive incentives with regulatory approval milestones.

This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.